INO: Summary for INOVIO BIOMED CORP - Yahoo! Canada Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 2:16am EST - Canadian Markets open in 7 hours and 14 minutes.

To create a watchlist or portfolio of shares, Sign-in or Register

Inovio Biomedical Corporation (INO)

On Feb 9: 1.18 USD

0.05 (4.07%)

MORE ON INO

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

INOVIO BIOMED CORP (AMEX:INO) Delayed quote data

Last Trade:	1.18 USD
Trade Time:	Feb 9
Change:	0.05 (4.07%)
Prev Close:	1.23
Open:	1.23
Bid:	N/A
Ask:	N/A
1y Target Est:	4.00

Day's Range:	1.10 - 1.25
52wk Range:	0.18 - 3.40
Volume:	400,270
Avg Vol (3m):	670,397
Market Cap:	120.51M
P/E (ttm):	N/A
EPS (ttm):	-0.34
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y max

Free Annual Reports

Add INO to Portfolio

Download Data

HEADLINES

•	Inovio Biomedical Cervical Cancer Therapeutic Vaccine Generates Dose-Related Immune Response in Clinical Trial
	Business Wire (Mon, Feb 8)

•	Swine Flu Antiviral Helps BioCryst Crush Estimates in Q4
	Indie Research (Thu, Feb 4)

•	Inovio Biomedical to Present at BIO CEO & Investor Conference
	Business Wire (Wed, Feb 3)

•	Inovio Unveils Skin Electroporation Technology for Delivering DNA Vaccines
	Business Wire (Wed, Jan 27)

•	Inovio Biomedical to Present at Partnering and Vaccine Conferences
	Business Wire (Tue, Jan 19)

•	Inovio Expands DNA Vaccine Intellectual Property License with University of Pennsylvania
	Business Wire (Mon, Jan 11)

•	VGX Animal Healths Growth Hormone Releasing Hormone Shows Advantages Compared to Current Growth Hormone Therapies Used in Pigs
	Business Wire (Thu, Jan 7)

•	Inovio Biomedical to Present at OneMedForum Investor Conference
	Business Wire (Thu, Jan 7)

•	Inovio Appoints Dr. Mark Bagarazzi as Chief Medical Officer
	Business Wire (Tue, Jan 5)

•	Swine Flu Vaccine News Back From the Dead
	Indie Research (Tue, Dec 29)

More Headlines for INO...

ANALYST

EPS Est (next year) (Dec-09) :	-0.29
EPS Est (in 2 years) (Dec-10) :	-0.23
Avg Rec (current)*:	1.0
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases.

Full Company Profile

Add to Portfolio

Email to a Friend

•